The Microdose Array Print (MAP) Technology has shown potential in clinical trials, providing the possibility of more accurate ocular drug delivery than traditional eye droppers
Press Release
–
Dec 22, 2022 06:01 PST
NEW YORK, December 22, 2022 (Newswire.com)
–
While medical devices have seen incredible advancements over the last 100 years, ocular drug delivery systems have seen minimal progress; the standard eye dropper used today has gone largely unchanged in the last century. Eyenovia, Inc. (NASDAQ: EYEN), a pre-commercial ophthalmic technology company developing a pipeline of late-stage microdose array print (MAP™) therapeutics, is developing one of the first microdosing systems that aims…
